You Own Wall Street › Funds › Franklin Biotechnology Discovery Fund

Franklin Biotechnology Discovery Fund (FBDIX) proxy voting record 2026

Three of its ballots from this season. Vote first, then see what it did with the shares your savings paid for.

The question on the ballot

As filed

Franklin Strategic Series files this fund's proxy votes with the SEC once a year. This is what it did with the shares your retirement savings paid for.

SourceProxy-voting record filed by Franklin Strategic Series on 2026-08-21 · open the filing · vote table (proxyvote.xml, 4.5 MB)

TickersFBDIX (CLASS A), FTDZX (ADVISOR CLASS), FRBRX (Class R6), FBTDX (Class C) · share classes of one fund, with one proxy-voting record · as listed in its latest SEC filing of proxy votes

How it voted, by issue

Fund companies sometimes file the same proposal under different subjects. So that funds can be compared, each proposal is counted under the subject most of the filings we read gave it, the same for every fund on this site. On management's own executive pay resolutions, this fund voted in favour 88% of the time across 50 votes.

IssueProposals facedBackedShare backed
Climate & environment100%
Corporate governance44100%
Other social issues200%

Ballots it voted

Gilead Sciences, Inc. · 30 April 2026 · put on the ballot by shareholder · Climate & environment

A report on the risks of ESG and DEI executive compensation metrics

AGAINST  Franklin Biotechnology Discovery Fund voted with 403,148 shares

“To vote on a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics, if properly presented at the Annual Meeting.”

SourceFranklin Strategic Series, Form N-PX filed 2026-08-21 · accession 0001193125-26-360729 · series S000006882 · open the filing

Gilead Sciences, Inc. · 30 April 2026 · put on the ballot by shareholder

Should the person who runs Gilead Sciences also chair the board that supervises them?

Shareholders asked the company to require that the chair of the board be an independent director rather than the chief executive, so that the body overseeing management is not led by the person being overseen.

FOR  Franklin Biotechnology Discovery Fund voted with 403,148 shares

“To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting.”

SourceFranklin Strategic Series, Form N-PX filed 2026-08-21 · accession 0001193125-26-360729 · series S000006882 · open the filing

Amgen Inc. · 19 May 2026 · put on the ballot by shareholder

Should the person who runs Amgen also chair the board that supervises them?

Shareholders asked the company to require that the chair of the board be an independent director rather than the chief executive, so that the body overseeing management is not led by the person being overseen.

FOR  Franklin Biotechnology Discovery Fund voted with 141,974 shares

“Stockholder proposal to require an independent board chairman.”

SourceFranklin Strategic Series, Form N-PX filed 2026-08-21 · accession 0001193125-26-360729 · series S000006882 · open the filing

Eli Lilly and Company · 4 May 2026 · put on the ballot by shareholder · Social

Should Eli Lilly and disclose what it lobbies for?

Shareholders asked for a report on the company’s lobbying: what it spends, which trade associations receive its money, what positions those bodies take, and who inside the company decides.

AGAINST  Franklin Biotechnology Discovery Fund voted with 14,071 shares

“Shareholder proposal to prepare an annual lobbying report.”

SourceFranklin Strategic Series, Form N-PX filed 2026-08-21 · accession 0001193125-26-360729 · series S000006882 · open the filing

Gilead Sciences, Inc. · 30 April 2026 · put on the ballot by shareholder · Social

A report on the impact of extended patent exclusivities on patient access

AGAINST  Franklin Biotechnology Discovery Fund voted with 403,148 shares

“To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting.”

SourceFranklin Strategic Series, Form N-PX filed 2026-08-21 · accession 0001193125-26-360729 · series S000006882 · open the filing

Other funds Franklin Strategic Series votes

The same filer reports these alongside this one, in the same annual filing.

Franklin Growth Opportunities Fund83% for exec payFranklin Natural Resources Fund93.3% for exec payFranklin Small Cap Growth Fund83.1% for exec payFranklin Small-Mid Cap Growth Fund92.9% for exec payFranklin Templeton SMACS: Series E92.9% for exec pay

No 401(k) plan we index offers this fund. Its record is here because the fund files it with the SEC, as every fund must: whoever holds it, in an IRA, a brokerage account or a plan we have not indexed, the fund votes those shares as shown on this page.

More funds no plan we index offers, and how each voted →